Shaking Up The Psychiatry Paradigm
Sponsored by: GlobalData
Date: 19 September
Days to go: 3
Time: 4PM BST/11AM EST
Current and Future Treatment Opportunities in the Psychological Disorders Landscape
This year has already seen several newsworthy developments for psychological disorders. In March, the FDA gave Sage Therapeutics’ Zulresso the nod for postpartum depression (PPD). But then in July, Intra-Cellular’s shares crashed 25% after the FDA review date for its schizophrenia drug lumateperone was delayed. The remainder of the second half and the start of 2020 look just as busy in terms of drug trial readouts, approvals and market launches in this therapeutic area.
During our Psychiatry Paradigm webinar, Senior Reporter Shuan Sim will discuss what his investigative reporting has turned up on future, high-impact drug development events in depression, schizophrenia, dementia-related psychosis and attention deficit hyperactivity disorder (ADHD). For example, despite Zulresso’s approval, Shuan reported that experts were unconvinced about payer coverage. The webinar will also dive into Sage’s other depression therapy, SAGE-217, as well as Minerva’s MIN-117 and Axsome’s AXS-05.
In the schizophrenia realm, Minerva is taken to task by experts, this time for its MIN-101. Similarly, Noven’s 2020 launch target for transdermal asenapine came under scrutiny. The webinar will also discuss expectations for Acadia’s Nuplazid Phase III in dementia-related psychosis and uptake potential of Supernus’ SPN-810 in ADHD.
During the webinar, Jennifer C. Smith-Parker, GlobalData’s Senior Editor, will moderate the discussion and the audience Q&A session following the presentation.
Speaker: Shuan Sim,
Shuan Sim has a Bachelor’s degree in linguistics and journalism from New York University. He had previously worked in various trade publications covering technology, precious metals and diamond trade and more. Shuan has worked as a breaking news reporter covering Asia and an international reporter in the Czech Republic. He’s also fluent in Mandarin and proficient in Japanese.
Moderator: Jennifer C. Smith-Parker,
Jennifer C. Smith-Parker is an award-winning healthcare journalist with a deep knowledge of the US and European pharmaceutical, regulatory and pricing/reimbursement sector. She manages a team of six journalists and analysts in the London and New York offices of GlobalData. She works closely with other management on editorial strategy and output, mentors and trains junior reporters and is responsible for wide-ranging editorial projects.
Jennifer moderates small group sessions and attends conferences as a BPI/GlobalData representative, interacts with C-level executives and has a database of regulatory, reimbursement and healthcare sources that she has maintained excellent relationships with over the years.
Key Learning Objectives
- In treatment-resistant depression, gain insight on challenges in trial design and the payer environment
- Find out how schizophrenia therapies in development stack up against existing options
- Get nuanced analysis on key and forthcoming treatments in dementia psychosis and in ADHD
- Managers/Senior Managers/Associate Directors/Directors of :
- Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy/Intelligence
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers